GR1007816B - Βιολογικος δεικτης - Google Patents

Βιολογικος δεικτης

Info

Publication number
GR1007816B
GR1007816B GR20110100593A GR20110100593A GR1007816B GR 1007816 B GR1007816 B GR 1007816B GR 20110100593 A GR20110100593 A GR 20110100593A GR 20110100593 A GR20110100593 A GR 20110100593A GR 1007816 B GR1007816 B GR 1007816B
Authority
GR
Greece
Prior art keywords
subject
biomaker
aqp1
autoantibodies
prognosis
Prior art date
Application number
GR20110100593A
Other languages
English (en)
Inventor
Σωκρατης Ιωαννη Τζαρτος
Ιωαννης Σωκρατη Τζαρτος
Χρηστος Δημοσθενη Στεργιου
Κωνσταντινος Επαμεινωνδα Κυλιντηρεας
Original Assignee
Σωκρατης Ιωαννη Τζαρτος
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Σωκρατης Ιωαννη Τζαρτος filed Critical Σωκρατης Ιωαννη Τζαρτος
Priority to GR20110100593A priority Critical patent/GR1007816B/el
Priority to US14/352,562 priority patent/US20150125514A1/en
Priority to ES12772445T priority patent/ES2823652T3/es
Priority to PCT/IB2012/054142 priority patent/WO2013057599A1/en
Priority to EP12772445.8A priority patent/EP2769220B8/en
Publication of GR1007816B publication Critical patent/GR1007816B/el

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
    • G01N33/538—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody by sorbent column, particles or resin strip, i.e. sorbent materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Rehabilitation Therapy (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Mycology (AREA)

Abstract

Μία μέθοδος για τη διάγνωση, την πρόγνωση ή τη θεραπεία αυτοάνοσου νοσήματος σε ασθενή, η οποία μέθοδος περιλαμβάνει την ανίχνευση αυτοαντισωμάτων υδατοπορίνης-1 (AQP1) σε δείγμα που λαμβάνεται από τον εν λόγω ασθενή.
GR20110100593A 2011-10-17 2011-10-17 Βιολογικος δεικτης GR1007816B (el)

Priority Applications (5)

Application Number Priority Date Filing Date Title
GR20110100593A GR1007816B (el) 2011-10-17 2011-10-17 Βιολογικος δεικτης
US14/352,562 US20150125514A1 (en) 2011-10-17 2012-08-14 Biomarker
ES12772445T ES2823652T3 (es) 2011-10-17 2012-08-14 Biomarcador de enfermedad autoinmunitaria
PCT/IB2012/054142 WO2013057599A1 (en) 2011-10-17 2012-08-14 Biomarker
EP12772445.8A EP2769220B8 (en) 2011-10-17 2012-08-14 Biomarker for autoimmune disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GR20110100593A GR1007816B (el) 2011-10-17 2011-10-17 Βιολογικος δεικτης

Publications (1)

Publication Number Publication Date
GR1007816B true GR1007816B (el) 2013-01-28

Family

ID=47018295

Family Applications (1)

Application Number Title Priority Date Filing Date
GR20110100593A GR1007816B (el) 2011-10-17 2011-10-17 Βιολογικος δεικτης

Country Status (5)

Country Link
US (1) US20150125514A1 (el)
EP (1) EP2769220B8 (el)
ES (1) ES2823652T3 (el)
GR (1) GR1007816B (el)
WO (1) WO2013057599A1 (el)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101794403B1 (ko) * 2015-04-29 2017-11-06 서울대학교산학협력단 쇼그렌증후군 특이적 항체반응 검사를 이용한 쇼그렌증후군 진단방법
KR101966515B1 (ko) * 2017-04-12 2019-04-05 서울대학교산학협력단 아쿠아포린 5에 대한 자가항체를 특이적으로 인식하는 에피토프 펩타이드 및 그 용도
CN108129563B (zh) * 2018-01-12 2020-12-01 沈阳眼产业技术研究院有限公司 一种抗aqp4的小分子抗体及其应用
CN112535726B (zh) * 2019-09-05 2023-09-12 南京安吉生物科技有限公司 一种肿瘤标志物aquaporin 2蛋白及其应用
CN114264818B (zh) * 2021-12-01 2023-02-03 陕西脉元生物科技有限公司 一种自身免疫系统疾病标志物抗asap2自身抗体及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5741671A (en) * 1991-12-12 1998-04-21 The Johns Hopkins University Isolation cloning and expression of transmembrane water channel aquaporin 1(AQP1)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1171374A (en) 1981-04-13 1984-07-24 Takeda Chemical Industries, Ltd. Pseudo-aminosugars, their production and use
US4708713A (en) 1984-11-16 1987-11-24 Anisa Medical, Inc. Method and system for removing immunosuppressive components from the blood of mammals
US5258503A (en) 1987-09-08 1993-11-02 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Autoantibody adsorbent and apparatus for removing autoantibodies using the same
US5324638A (en) 1992-05-13 1994-06-28 Sloan-Kettering Institute For Cancer Research Brain transcription factor, nucleic acids encoding same and uses thereof
DE4227695C1 (de) 1992-08-21 1993-10-07 Fresenius Ag Zentrifuge zum Auftrennen von Blut in seine Bestandteile
US5676644A (en) 1995-06-07 1997-10-14 Cobe Laboratories, Inc. Extracorporeal blood processing methods and apparatus
WO1997017369A2 (en) 1995-11-09 1997-05-15 Trustees Of Boston University Dna comprising a neuron-specific transcriptional promoter and its use in a gene therapy vector

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5741671A (en) * 1991-12-12 1998-04-21 The Johns Hopkins University Isolation cloning and expression of transmembrane water channel aquaporin 1(AQP1)

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DENKER B M ET AL: "Identification, purification, and partial characterization of a novel Mr 28,000 integral membrane protein from erythrocytes and renal tubules.", THE JOURNAL OF BIOLOGICAL CHEMISTRY 25 OCT 1988 LNKD- PUBMED:3049610, vol. 263, no. 30, 25 October 1988 (1988-10-25), pages 15634 - 15642, XP002679358, ISSN: 0021-9258 *
ELEONORA FOGLIO ET AL: "Aquaporins and Neurodegenerative Diseases", CURRENT NEUROPHARMACOLOGY, vol. 8, no. 2, 1 June 2010 (2010-06-01), pages 112 - 121, XP055031684, ISSN: 1570-159X, DOI: 10.2174/157015910791233150 *
NIKOLOV, NP ET AL.: "Autoantibodies against aquaporins in primary Sjögren's Syndrome (pSS)", 1 January 2008 (2008-01-01), XP002679357, Retrieved from the Internet <URL:https://acr.confex.com/acr/2008/webprogram/Paper3359.html> [retrieved on 20120705] *
SMITH B L ET AL: "Human red cell aquaporin CHIP. I. Molecular characterization of ABH and Colton blood group antigens.", THE JOURNAL OF CLINICAL INVESTIGATION SEP 1994 LNKD- PUBMED:7521882, vol. 94, no. 3, September 1994 (1994-09-01), pages 1043 - 1049, XP055031929, ISSN: 0021-9738 *

Also Published As

Publication number Publication date
EP2769220B1 (en) 2020-07-15
ES2823652T3 (es) 2021-05-07
US20150125514A1 (en) 2015-05-07
WO2013057599A1 (en) 2013-04-25
EP2769220A1 (en) 2014-08-27
EP2769220B8 (en) 2020-11-18

Similar Documents

Publication Publication Date Title
EP2539470A4 (en) METHODS FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF AUTOIMMUNE DISEASES
MX367046B (es) Marcadores especificos de via para diagnosticar sindrome del intestino irritable.
WO2011095623A3 (en) miRNA IN THE DIAGNOSIS OF OVARIAN CANCER
WO2012054639A3 (en) Nmr systems and methods for the rapid detection of analytes
WO2014028884A3 (en) Cancer diagnostics using biomarkers
MX340453B (es) Biomarcadores para cancer de pulmon.
EA201391245A1 (ru) Интеррогативные клеточные анализы и их применение
TN2013000464A1 (en) Biomarkers for hedgehog inhibitor therapy
WO2013107459A3 (en) Microrna for diagnosis of pancreatic cancer and/or prognosis of patients with pancreatic cancer by blood samples
MX2017000840A (es) Metodo para predecir el resultado de un tratamiento con aflibercept de un paciente que se sospecha que padece un cancer.
IN2012DN02521A (el)
MX2020010947A (es) Metodos de tratamiento de enfermedad de alzheimer.
MX2016004167A (es) Diagnostico y tratamiento del sindrome del intestino irritable y la enfermedad inflamatoria intestinal.
WO2010115745A3 (en) Biomarkers, methods and kits for the diagnosis of rheumatoid arthritis
CY1122360T1 (el) Μεθοδος για τη διαγνωση της νοσου niemann-pick
EP2569635A4 (en) METHODS OF DIAGNOSING AND TREATING ENCEPHALITY OR EPILEPSY
GR1007816B (el) Βιολογικος δεικτης
WO2012122374A3 (en) Non-invasive methods for diagnosing chronic organ transplant rejection
EP2723866A4 (en) METHOD FOR THE PROGNOSIS AND / OR DIAGNOSIS OF NEURODEEGENERATIVE DISEASES, METHOD FOR IDENTIFYING COMPOUND CANDIDATES AND COMPOUNDS FOR THE TREATMENT OF NEURODEGENATIVE DISEASES
WO2014078468A3 (en) Biomarkers for predicting clinical response of cancer patients to treatment with immunotherapeutic agent
WO2014091490A3 (en) Diagnosis of autoimmune diseases using a specific antibody profile
WO2013028807A3 (en) Renal cell carcinoma biomarkers and uses thereof
HK1250751A1 (zh) 基於脂肪組織樣本預測和/或診斷疾病的方法及方法套件
WO2016012864A3 (en) Biomarkers for anderson-fabry disease
WO2014072832A3 (en) Biomarkers for cervical cancer

Legal Events

Date Code Title Description
PG Patent granted

Effective date: 20130225